

Andy Goren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6314793/publications.pdf>

Version: 2024-02-01

71
papers

1,779
citations

361413

20
h-index

315739

38
g-index

87
all docs

87
docs citations

87
times ranked

2060
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study. <i>Annals of Thyroid</i> , 2022, 6, 7-7.	1.0	6
2	Novel cannabidiol aspartame combination treatment (JWâ€100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized doubleâ€blinded placeboâ€controlled interventional study. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 1647-1650.	1.6	7
3	SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 343-346.	1.6	6
4	Rosacea management: A comprehensive review. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 1895-1904.	1.6	24
5	Androgens and COVIDâ€19. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 3176-3180.	1.6	6
6	Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e24-e26.	2.4	8
7	Antiâ€androgens may protect against severe COVIDâ€19 outcomes: results from a prospective cohort study of 77 hospitalized men. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e13-e15.	2.4	54
8	Clinical symptoms of hyperandrogenic women diagnosed with COVIDâ€19. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e101-e104.	2.4	30
9	Reply to comment on: The Gabrin sign. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e149-e150.	1.2	0
10	Androgenetic alopecia may be associated with weaker COVID-19â€cell immune response: An insight into a potential COVID-19 vaccine booster. <i>Medical Hypotheses</i> , 2021, 146, 110439.	1.5	12
11	Spirolactone in adolescent acne vulgaris. <i>Dermatologic Therapy</i> , 2021, 34, e14680.	1.7	7
12	5â€alphaâ€reductase inhibitors are associated with reduced frequency of COVIDâ€19 symptoms in males with androgenetic alopecia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e243-e246.	2.4	42
13	Androgen receptor genetic variant predicts COVIDâ€19 disease severity: a prospective longitudinal study of hospitalized COVIDâ€19 male patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e15-e17.	2.4	27
14	Novel cannabidiol sunscreen protects keratinocytes and melanocytes against ultraviolet B radiation. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 1350-1352.	1.6	10
15	The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. <i>Cureus</i> , 2021, 13, e12565.	0.5	9
16	Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Cureus</i> , 2021, 13, e13492.	0.5	46
17	Nonablative radiofrequency for the treatment of androgenetic alopecia: An openâ€label study. <i>Dermatologic Reviews</i> , 2021, 2, 129-131.	0.5	0
18	Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users. <i>BMJ Case Reports</i> , 2021, 14, e241572.	0.5	20

#	ARTICLE	IF	CITATIONS
19	Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial “ Biochemical). <i>Cureus</i> , 2021, 13, e13047.	0.5	51
20	Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism. <i>International Journal of Dermatology</i> , 2021, 60, e267-e268.	1.0	4
21	Surgical interventions for androgenetic alopecia. <i>Dermatological Reviews</i> , 2021, 2, 132-135.	0.5	0
22	Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. <i>New Microbes and New Infections</i> , 2021, 43, 100915.	1.6	20
23	Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 668698.	2.6	43
24	COVID-19, androgens, and androgenic alopecia. <i>Dermatological Reviews</i> , 2021, 2, 146-153.	0.5	7
25	Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial. <i>Cureus</i> , 2021, 13, e20691.	0.5	19
26	Oral minoxidil bioactivation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e40-e41.	2.4	16
27	Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients. <i>Dermatologic Therapy</i> , 2020, 33, e13195.	1.7	7
28	Can we halt male androgenetic alopecia progression without antiandrogenic drugs?. <i>Dermatologic Therapy</i> , 2020, 33, e13197.	1.7	2
29	Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. <i>Dermatologic Therapy</i> , 2020, 33, e13174.	1.7	5
30	Are night shift workers at an increased risk for COVID-19?. <i>Medical Hypotheses</i> , 2020, 144, 110147.	1.5	24
31	Androgen sensitivity in COVID-19 and antiandrogens: Prospective data are still needed. <i>Dermatologic Therapy</i> , 2020, 33, e14166.	1.7	3
32	Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). <i>Medical Hypotheses</i> , 2020, 143, 110112.	1.5	45
33	Novel “After Minoxidil” spray improves topical minoxidil compliance and hair style manageability. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2647-2649.	1.6	4
34	Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e401-e402.	1.2	6
35	Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e453-e454.	1.2	38
36	Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 453.	2.6	36

#	ARTICLE	IF	CITATIONS
37	STAT3 mutated hyperimmunoglobulin E syndrome with perianal skin tags and erosions: A case report. <i>Dermatologic Therapy</i> , 2020, 33, e13333.	1.7	1
38	Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e799-e800.	2.4	5
39	Allergic contact dermatitis in patients with frontal fibrosing alopecia: An international multi-center study. <i>Dermatologic Therapy</i> , 2020, 33, e13560.	1.7	9
40	Androgen sensitivity gateway to COVID-19 disease severity. <i>Drug Development Research</i> , 2020, 81, 771-776.	2.9	126
41	Safety measures in dermatology help minimize spread of COVID-19. <i>Dermatologic Therapy</i> , 2020, 33, e13773.	1.7	5
42	What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. <i>Dermatologic Therapy</i> , 2020, 33, e13365.	1.7	52
43	Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia. <i>Lasers in Medical Science</i> , 2020, 35, 1239-1244.	2.1	10
44	Erosive pustular dermatosis of the scalp: a multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1348-1354.	2.4	19
45	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 308-309.	1.2	182
46	Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 1542-1543.	1.6	75
47	A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 1545-1547.	1.6	149
48	Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The GABRA1 sign. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 680-682.	1.2	136
49	Clock genes may drive seasonal variation in SARS-CoV-2 infectivity: are we due for a second wave of COVID-19 in the fall?. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2020, 34, 1455-1457.	0.7	4
50	Platelet rich plasma in androgenetic alopecia: A systematic review. <i>Dermatologic Therapy</i> , 2019, 32, e12837.	1.7	14
51	Mission impossible: Dermal delivery of growth factors via microneedling. <i>Dermatologic Therapy</i> , 2019, 32, e12897.	1.7	12
52	Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. <i>Dermatologic Therapy</i> , 2019, 32, e12915.	1.7	12
53	Frontal pattern hair loss among Chinese women is frequently associated with ponytail hairstyle. <i>Dermatologic Therapy</i> , 2019, 32, e12784.	1.7	6
54	Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. <i>Dermatologic Therapy</i> , 2018, 31, e12688.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Anterior, frontal congenital triangular alopecia, redundancy in therapy without improvement. <i>Dermatologic Therapy</i> , 2018, 31, e12698.	1.7	6
56	Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. <i>Dermatologic Therapy</i> , 2018, 31, e12741.	1.7	16
57	Minoxidil in the treatment of androgenetic alopecia. <i>Dermatologic Therapy</i> , 2018, 31, e12686.	1.7	41
58	The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2018, 32, 937-940.	0.7	6
59	Prevalence of hair shedding among women. <i>Dermatologic Therapy</i> , 2017, 30, e12415.	1.7	8
60	Melanin of the nipple areola complex. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2017, 31, 237-238.	0.7	1
61	Management of chronic pruritus with a UV filtering topical cream. <i>Dermatologic Therapy</i> , 2016, 29, 101-103.	1.7	1
62	Doppler laser imaging predicts response to topical minoxidil in the treatment of female pattern hair loss. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2016, 30, 131-4.	0.7	2
63	Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2016, 30, 1153-1155.	0.7	11
64	Clinical utility and validity of minoxidil response testing in androgenetic alopecia. <i>Dermatologic Therapy</i> , 2015, 28, 13-16.	1.7	52
65	Prodrugs. , 2015, , 1487-1491.		1
66	Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2623-2627.	1.8	5
67	Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy. <i>Dermatologic Therapy</i> , 2014, 27, 260-263.	1.7	6
68	Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation. <i>Dermatologic Therapy</i> , 2014, 27, 195-197.	1.7	20
69	Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. <i>Dermatologic Therapy</i> , 2014, 27, 252-254.	1.7	28
70	Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. <i>Dermatologic Therapy</i> , 2014, 27, 171-173.	1.7	38
71	Efficacy of Proxalutamide (GT0918) in Hospitalized COVID-19 Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0